U.S. Software Stock News

uniQure (QURE) is in focus after first quarter results showed revenue of US$3.56 million and a net loss of US$53.54 million, alongside fresh regulatory progress for its Huntington’s disease gene therapy, AMT-130. See our latest analysis for uniQure. The stock has reacted strongly to the recent earnings update and regulatory progress on AMT-130, with a 1-month share price return of 79.84% and a 1-year total shareholder return of 110.34%, which may indicate building momentum rather than a...

Q1 earnings set the tone for Hanover Insurance Group stock Hanover Insurance Group (THG) opened the quarter in focus after reporting first quarter results with revenue of US$1,701.4 million and net income of US$186.8 million, alongside higher diluted EPS from continuing operations. See our latest analysis for Hanover Insurance Group. Investors appear to be reacting positively to the earnings update, with a 1-day share price return of 1.52% and a 30-day share price return of 6.99%. The 3-year...

In April 2026, Etsy, Inc. reported first-quarter 2026 results showing sales of US$631.28 million and net income of US$69.68 million, a return to profitability compared with a net loss a year earlier. The company coupled this profit recovery with an ongoing share repurchase effort that has retired over 17.05 million shares under its October 2024 buyback, while emphasizing a human-centric marketplace strategy focused on seller stories and identity. We’ll now examine how Etsy’s shift toward a...

Recent performance snapshot for V2X (VVX) V2X (VVX) has drawn investor interest after recent share price moves, with the stock last closing at US$70.08 and posting positive returns over the past month, past 3 months, and year to date. The company provides mission solutions and support services to defense and government customers. Its recent share performance sits alongside reported annual revenue of US$4.72b and net income of US$88.7 million. See our latest analysis for V2X. Even after a...

Akamai Technologies (AKAM) is back in focus after securing a seven year, US$1.8b cloud infrastructure commitment from a leading frontier AI company, alongside first quarter results that topped revenue and earnings estimates. See our latest analysis for Akamai Technologies. The earnings beat, AI cloud contract and recent buyback activity have coincided with a sharp shift in sentiment. Akamai’s 30 day share price return of 61.7% and 1 year total shareholder return of 87.47% point to strong...

WisdomTree (WT) has been in focus after launching the WisdomTree Efficient Rare Earth Plus Strategic Metals Fund (WDIG) and reporting first quarter results that topped Wall Street expectations on both revenue and adjusted earnings. See our latest analysis for WisdomTree. Recent launches like WDIG, the tokenized treasury partnership with Stable Sea and the latest quarterly update have all landed against a strong backdrop. A 1 year total shareholder return of 102.6% and a year to date share...

Bitmine Immersion Technologies (BMNR) has caught investor attention after chairman Thomas Jong Lee signaled a slower pace of Ethereum purchases, and the company outlined an expanded US$4b share repurchase program. See our latest analysis for Bitmine Immersion Technologies. Bitmine Immersion Technologies’ recent communications around moderating Ethereum purchases and expanding the share repurchase authorization come after a period of sharp swings, with the latest 90-day share price return of...

Coty (COTY) is back in focus after recent earnings showed pressure on sales, wider losses, and withdrawn guidance, while a securities class action lawsuit adds a separate layer of uncertainty for shareholders. See our latest analysis for Coty. Recent selling pressure has been heavy, with the 1 year total shareholder return down 50.7% and the 3 year total shareholder return down 78.2%. At the same time, the 30 day share price return is up 13.82%, suggesting only a short term bounce after weak...

Event driven focus on Mosaic ahead of earnings Mosaic (MOS) is in the spotlight as investors brace for its Q1 earnings on May 11, with expectations for weaker profitability alongside higher revenue and fresh attention from FMR LLC’s newly disclosed passive 9.1% stake. See our latest analysis for Mosaic. The recent weakness in Mosaic’s share price, with the stock down 10.38% on a 1 month share price basis and a 30.58% decline in 1 year total shareholder return, suggests momentum has been...

Enliven Therapeutics (ELVN) is back in focus after a cluster of analyst rating confirmations linked to Merck’s supportive comments on similar therapies, following the company’s recent first quarter update and clinical progress on ELVN-001. See our latest analysis for Enliven Therapeutics. At a share price of $40.75, Enliven’s recent moves reflect a sharp year to date share price return of 162.23% and a 114.36% one year total shareholder return, even after a 10.08% share price pullback over...

Martin Marietta Materials (MLM) has drawn attention after reporting first quarter 2026 sales of US$1,362 million and net income of US$1,513 million, alongside reaffirmed full year revenue and earnings guidance. See our latest analysis for Martin Marietta Materials. Despite the reaffirmed guidance and ongoing share repurchases, the stock has given up some ground in recent months, with the 90 day share price return down 16.63% even as the 5 year total shareholder return sits at 61.90%. This...

In late April 2026, Intellia Therapeutics completed a US$180.00 million follow-on common stock offering and reported positive Phase 3 HAELO trial results alongside initiating a rolling FDA biologics license application for its one-time CRISPR-based hereditary angioedema therapy, lonvo-z. The combination of strong late-stage clinical data, multiple expedited regulatory designations, and fresh equity capital highlights how Intellia is positioning lonvo-z as a potential first-in-class, one-time...

In early May 2026, Alcoa Corporation filed a US$506.08 million shelf registration for 8,000,000 common shares linked to its employee stock ownership plan and confirmed a quarterly dividend of US$0.10 per share payable on June 5, 2026. This combination of an employee-focused equity program and a maintained cash dividend underscores Alcoa’s parallel focus on workforce ownership and ongoing capital returns. With Wells Fargo’s upgrade reflecting increased confidence in Alcoa’s outlook, we’ll now...

Recent performance snapshot Natural Resource Partners (NRP) has drawn investor attention after recent price weakness, with the stock down 6.7% over the past month and 9.6% over the past 3 months, despite a 7.2% gain year to date. Over the past year, the total return of 18.3% contrasts with the recent pullback and has prompted some investors to recheck the fundamentals behind its mineral rights and soda ash focused business. See our latest analysis for Natural Resource Partners. Short term...

In late April 2026, ResMed reported higher third‑quarter and nine‑month sales and earnings, confirmed a US$0.60 quarterly dividend, completed its long-running share repurchase program, and announced that long-serving CFO Brett Sandercock would retire in May 2026 while remaining an advisor through 2027. The appointment of former Exact Sciences finance chief Aaron Bloomer as ResMed’s new CFO brings extensive global healthcare finance and capital allocation experience that could influence how...

AZZ Inc. recently executed a Seventh Amendment to its credit agreement, extending the maturity of its revolving credit commitments to May 7, 2029, while lowering interest rate margins, commitment fees, and letter of credit fees tied to its leverage ratios. This refinancing move reshapes AZZ’s capital structure by potentially reducing ongoing financing costs and giving the company a longer runway to fund operational and growth initiatives. We’ll now examine how this extended, lower-cost...

In the first quarter of 2026, Centuri Holdings reported revenue of US$723.17 million, up from US$550.08 million a year earlier, while reducing its net loss to US$9.53 million from US$17.94 million. Alongside this improvement, the company grew gross profit sharply, expanded its backlog to about US$6.50 billion, and reaffirmed its 2026 guidance while outlining multi-year growth targets. With revenue rising strongly and the backlog reaching about US$6.50 billion, we’ll now examine how this...

Waters (WAT) is back in focus after first quarter 2026 results beat expectations, aided by strong organic growth and the BD Biosciences and Diagnostic Solutions acquisitions, alongside higher full year 2026 financial guidance. See our latest analysis for Waters. Investors have responded quickly to the upgraded 2026 guidance, with the stock delivering a 17.64% 7 day share price return and an 8.60% 90 day share price return. However, year to date the share price return is down 7.02%, while the...

German American Bancorp (GABC) is back on investors’ radar after first quarter 2026 results showed net income of US$33.15 million, supported by higher net interest income and a much lower credit loss provision. See our latest analysis for German American Bancorp. The stock is trading at US$43.59 and, after a small 1-day share price decline, still shows a 12.11% year-to-date share price gain and a 78.21% three-year total shareholder return. This suggests momentum has been building over the...

Recent news around Kopin (KOPN) centers on its partnership with Fabric.AI, including a MicroLED Neural I/o chip program for AI data centers, new development funding, and fresh leadership for this joint effort. See our latest analysis for Kopin. The recent news flow appears to have coincided with sharp share price momentum, with a 30 day share price return of 103.38% and a 90 day share price return of 130.21%. This has contributed to a very strong 1 year total shareholder return of 249.03% and...

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$866.56 million to a net loss of US$2.81 million while still beating analyst expectations on both revenue and earnings per share. The company also released positive 24-month interim data for Huntington’s disease therapy votoplam and raised its 2026 product revenue guidance, underscoring how a strong Sephience launch and advancing...

Novavax (NVAX) recently reported first quarter 2026 results that beat revenue and loss expectations, helped by a US$30 million upfront payment from a new Pfizer licensing deal and fresh Matrix M partnership activity. See our latest analysis for Novavax. The stock has rallied strongly in recent months, with a 7 day share price return of 16.5% and a year to date share price return of 29.5%, although the 5 year total shareholder return remains down 92.4%. If you are looking beyond vaccines and...

Liberty Broadband Corporation has reported past first-quarter 2026 results, with net income of US$203 million versus US$268 million a year earlier, and basic earnings per share from continuing operations of US$1.42 compared with US$1.64. The year-over-year decline in both net income and earnings per share highlights pressure on profitability at a time when investors are closely watching Liberty Broadband’s ongoing structural changes and upcoming transactions. We’ll now examine how this...

Wendy's (WEN) stock is in focus after first quarter 2026 results topped market expectations on revenue and adjusted earnings, while management reaffirmed full year guidance and confirmed a quarterly dividend alongside a new China expansion agreement. See our latest analysis for Wendy's. The latest results and China expansion plan sparked a 1 day share price return of 4.51% to US$6.95, but the share price is still down 14.93% year to date and the 1 year total shareholder return is down 39.06%,...